Article

BMI Matters: Predicting Cardiovascular Event Risk

Author(s):

While various epidemiological studies have shown obesity to be linked with inflammation and with increased cardiovascular risk, the inflammatory marker C-reactive protein (CRP) takes it a step further, strongly predicting the incidence of cardiovascular events.

While various epidemiological studies have shown obesity to be linked with inflammation and with increased cardiovascular risk, the inflammatory marker C-reactive protein (CRP) takes it a step further, strongly predicting the incidence of cardiovascular events.

Whether CRP is equally predictive of cardiovascular event risk in obese patients and in non-obese subjects is not known and will be addressed in a presentation by Christoph H. Saely, MD, VIVIT Institute, Academic Teaching Hospital, Feldkirch, Austria at the American College of Cardiology (ACC) 64th Annual Scientific Meeting.

During a follow-up 10-year period, the researchers recorded cardiovascular events in a large population of 1,731 patients undergoing coronary angiography — evaluating the established or suspected stable coronary artery disease (CAD).

CRP was reported significantly higher in non-obese subjects (n=1,367) than obese individuals (n=364; 0.6±1.5 vs. 0.5±0.8 mg/dl; p<0.001). Meanwhile, approximately a quarter of the patients were reported to have suffered vascular events.

While CRP appeared to be a strong, independent predictor of vascular events in non-obese subjects, it did not show similar results in the obese group. However, an interaction term of BMI x CRP was found to be significant, demonstrating that the mass index weight considerably modified the power of CRP to predict vascular events.

“From the results of this large 10-year prospective cohort study we conclude that obesity significantly modulates the power of CRP to predict cardiovascular event risk among angiographied coronary patients,” wrote the authors.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.